Dominican company based in Santo Domingo · We only ship within the Dominican Republic · No international shippingDominican Republic only · No international shipping
ES Home Catalog Education COAs Calculator Founder
AOD-9604
Renova Verification
  • ✓≥99% purity by HPLC + mass spectrometry
  • ✓Independent Janoshik 3rd-party analysis
  • ✓−20°C lyophilized · 2–8°C reconstituted
🧪 View COA →
Home › Products › Metabolic Research › AOD-9604
← Back to catalog Metabolic ResearchAvailable

AOD-9604 (5 mg)

LipolyticGH fragmentFat burning
$160 USD5 mg/vial
🧪 Bacteriostatic water — needed to reconstitute the lyophilized vial
💰 Buy by volume
3+ of one
Save 15%
5+ of one
Save 25%
★ Wholesale
10+ of one
Save 40%
🔀 Mix & Match · across different products: 3+ items 10% · 5+ 15% · 7+ 20%
The best discount per product is applied automatically at checkout (they don't stack). Excludes bacteriostatic water; Retatrutide and Tirzepatide only get same-product volume. Can't be combined with promo codes.
🧪 COA❄️ Cold chain🛡️ Replacement guarantee🔒 Secure payment📦 Nationwide shipping🇺🇸 cGMP · ISO 9001 guidelines · COA

Fragment 176-191 of growth hormone — preserves GH's lipolytic action without its effects on IGF-1 or glucose.

  • Mechanism: GH fragment 176-191; lipolytic, does not activate the GH receptor or raise IGF-1 (mechanism not fully clear).
  • Evidence: Human obesity trials (Phase 2) did not meet the primary endpoint.
  • In context: Clinical efficacy not demonstrated.
Rango de investigación · SC
300–500 mcg per application · once daily (AM)
🔴 Research convention · SC convention (Phase 2 was oral)

Ranges cited in research literature. Not a usage recommendation. For research use only.

📋 Technical datasheet · Compound specifications
CompoundAOD-9604
Origin🇺🇸 From US-based suppliers that follow strict cGMP & ISO 9001 guidelines
FormLyophilized in sterile vial (or pre-mixed solution depending on SKU)
Molecular formulaC78H123N23O23S2
Molecular weight1817.07 g/mol
Sequence177-191 fragment of HGH + Tyr
Purity≥99% by HPLC + mass spectrometry (Janoshik Analytical)
StorageLyophilized: −20°C to −80°C, dry, dark · Reconstituted: 2–8°C · stability varies by peptide (see the reconstitution guide and the product COA)
Recommended solventBacteriostatic water (0.9% benzyl alcohol) or 0.9% saline
Cold chain2–8°C in transit · controlled thermal packaging
UseResearch Use Only (RUO). Not intended for human or veterinary use.

Typical values for this compound category. For product-specific data, see the corresponding COA at /en/coa/.

This product is exclusively for research purposes. Not intended for human use, consumption, or therapeutic applications. For laboratory use only under qualified supervision.

AOD-9604: research profile

AOD-9604 is a synthetic fragment of human growth hormone: amino acids 176 to 191 of the C-terminal end, with a tyrosine added at the N-terminus for stability. It was developed at Monash University (Australia) by Frank Ng's group and licensed to Metabolic Pharmaceuticals in the late 1990s. The design idea was to isolate the region of GH associated with lipid metabolism while leaving out the part responsible for growth and IGF-1 elevation.

In obese rodent models the fragment stimulated lipolysis and reduced lipogenesis without activating the GH receptor or altering glucose or IGF-1, which sets it apart from the full hormone. The proposed mechanism involves β3-adrenergic signaling in the adipocyte, although it was never fully characterized. The molecule carries a disulfide bridge between cysteines 182 and 189 that holds its conformation; without it, activity in in-vitro assays drops.

The clinical program was large for a peptide of this kind: several hundred participants in oral Phase 2 trials. In 2007 the Phase 2b obesity trial missed its primary endpoint and drug development stopped, although tolerability was good across studies. Since then AOD-9604 has existed as a research compound; laboratory convention uses the subcutaneous route, unlike the oral route of the trials, a nuance that matters when reading the literature. Renova's material is strictly for research use.

AOD-9604 technical data

ClassModified C-terminal fragment of hGH (hGH 176-191)
SequenceTyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa) · disulfide Cys182–Cys189
CAS221231-10-3
OriginMonash University / Metabolic Pharmaceuticals (Australia)
Regulatory statusOral Phase 2b obesity trial missed its primary endpoint in 2007; never approved as a drug
Difference from GHDoes not activate the GH receptor; no effect on IGF-1 or glucose in studies

Questions about AOD-9604

Is AOD-9604 growth hormone?

No. It is a 16-amino-acid fragment matching the tail end of GH (positions 176-191). In studies it does not activate the GH receptor, does not raise IGF-1 and does not affect glucose; it retains only the region associated with lipid metabolism.

What happened in the AOD-9604 clinical trials?

Metabolic Pharmaceuticals took the compound to oral Phase 2b in obesity. In 2007 the trial missed its primary efficacy endpoint and pharmaceutical development stopped. Tolerability was good, which is why it remains a compound of research interest.

Why does AOD-9604 have a disulfide bridge?

The cysteines at positions 182 and 189 form a bond that closes a loop and maintains the fragment's three-dimensional shape, as in native GH. It matters for stability: reducing that bridge inactivates the molecule in laboratory assays.

How does AOD-9604 relate to other compounds in the catalog?

It shares a research area with MOTS-c and 5-Amino-1MQ (energy and lipid metabolism) but through a different mechanism: it is the only direct GH derivative. Our 2026 fat-loss peptide guide compares them in the context of existing trials.

Related reading: AOD-9604: hGH Fragment for Lipolysis · Fat Loss: Complete Peptide Guide (2026)

Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.

Questions? Write us

Your Order

Your cart is empty